5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

4. Merus N.V. (NASDAQ:MRUS)

Biotechnology Value Fund’s Stake Value: $153,496,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 5.75%
Number of Hedge Fund Holders: 23

Merus N.V. (NASDAQ:MRUS), a Dutch biotechnology company, stands fourth on our list of the best biotech stocks to buy according to Mark Lampert. In Q2, BVF did not make any changes to its position in the company and holds over 7.2 million shares, valued at over $153.4 million. The company represents 5.75% of the hedge fund’s 13F portfolio.

In Q2, Merus N.V. (NASDAQ:MRUS) reported revenue of $12.38 million, showcasing a 103% year-over-year growth. The shares of the company rose 31% on October 7, when the company’s drug, MCLA-158, showed shrinkage of tumors in patients with neck and head cancer. Merus N.V. (NASDAQ:MRUS) gained 122.2% in the past year. This October, Citigroup lifted its price target on Merus N.V. (NASDAQ:MRUS) to $38, with a Buy rating on the shares.

As of Q2 2021, 23 hedge funds tracked by Insider Monkey were bullish on Merus N.V. (NASDAQ:MRUS), the same as in the previous quarter. The total worth of these stakes is $308.7 million.